Cargando…

RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families

Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelttari, Liisa M, Kiiski, Johanna I, Ranta, Salla, Vilske, Sara, Blomqvist, Carl, Aittomäki, Kristiina, Nevanlinna, Heli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404470/
https://www.ncbi.nlm.nih.gov/pubmed/25918678
http://dx.doi.org/10.1186/s40064-015-0880-3
_version_ 1782367495347240960
author Pelttari, Liisa M
Kiiski, Johanna I
Ranta, Salla
Vilske, Sara
Blomqvist, Carl
Aittomäki, Kristiina
Nevanlinna, Heli
author_facet Pelttari, Liisa M
Kiiski, Johanna I
Ranta, Salla
Vilske, Sara
Blomqvist, Carl
Aittomäki, Kristiina
Nevanlinna, Heli
author_sort Pelttari, Liisa M
collection PubMed
description Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage site. The RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3 facilitate the binding of RAD51 to DNA. While germline mutations in RAD51C and RAD51D are associated with high ovarian cancer risk and RAD51B polymorphisms with breast cancer, the contribution of RAD51, XRCC3, and XRCC2 is more unclear. To investigate the role of RAD51, XRCC3, and XRCC2 in breast cancer predisposition and to identify putative recurrent founder mutations in the Finnish population where such mutations have been observed in most of the currently known susceptibility genes, we screened 182 familial Finnish breast or ovarian cancer patients for germline variation in the RAD51and XRCC3 genes and 342 patients for variation in XRCC2, with a subset of the patients selected on the basis of decreased RAD51 protein expression on tumors. We also performed haplotype analyses for 1516 breast cancer cases and 1234 controls to assess the common variation in these genes. No pathogenic mutations were detected in any of the genes and the distribution of haplotypes was similar between cases and controls. Our results suggest that RAD51, XRCC3, and XRCC2 do not substantially contribute to breast cancer predisposition in the Finnish population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-0880-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4404470
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-44044702015-04-27 RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families Pelttari, Liisa M Kiiski, Johanna I Ranta, Salla Vilske, Sara Blomqvist, Carl Aittomäki, Kristiina Nevanlinna, Heli Springerplus Research Majority of the known breast cancer susceptibility genes have a role in DNA repair and the most important high-risk genes BRCA1 and BRCA2 are specifically involved in the homologous recombination repair (HRR) of DNA double-strand breaks. A central player in HRR is RAD51 that binds DNA at the damage site. The RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3 facilitate the binding of RAD51 to DNA. While germline mutations in RAD51C and RAD51D are associated with high ovarian cancer risk and RAD51B polymorphisms with breast cancer, the contribution of RAD51, XRCC3, and XRCC2 is more unclear. To investigate the role of RAD51, XRCC3, and XRCC2 in breast cancer predisposition and to identify putative recurrent founder mutations in the Finnish population where such mutations have been observed in most of the currently known susceptibility genes, we screened 182 familial Finnish breast or ovarian cancer patients for germline variation in the RAD51and XRCC3 genes and 342 patients for variation in XRCC2, with a subset of the patients selected on the basis of decreased RAD51 protein expression on tumors. We also performed haplotype analyses for 1516 breast cancer cases and 1234 controls to assess the common variation in these genes. No pathogenic mutations were detected in any of the genes and the distribution of haplotypes was similar between cases and controls. Our results suggest that RAD51, XRCC3, and XRCC2 do not substantially contribute to breast cancer predisposition in the Finnish population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40064-015-0880-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-02-24 /pmc/articles/PMC4404470/ /pubmed/25918678 http://dx.doi.org/10.1186/s40064-015-0880-3 Text en © Pelttari et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Pelttari, Liisa M
Kiiski, Johanna I
Ranta, Salla
Vilske, Sara
Blomqvist, Carl
Aittomäki, Kristiina
Nevanlinna, Heli
RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title_full RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title_fullStr RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title_full_unstemmed RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title_short RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
title_sort rad51, xrcc3, and xrcc2 mutation screening in finnish breast cancer families
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404470/
https://www.ncbi.nlm.nih.gov/pubmed/25918678
http://dx.doi.org/10.1186/s40064-015-0880-3
work_keys_str_mv AT pelttariliisam rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT kiiskijohannai rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT rantasalla rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT vilskesara rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT blomqvistcarl rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT aittomakikristiina rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies
AT nevanlinnaheli rad51xrcc3andxrcc2mutationscreeninginfinnishbreastcancerfamilies